Safety, feasibility of PrEP for adolescent men who have sex with men

September 5, 2017, The JAMA Network Journals

Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) was safe and well-tolerated in a study of adolescent men who have sex with men, although adherence to the daily medication waned and some HIV infections occurred among those with poor adherence, according to an article published by JAMA Pediatrics.

The U.S. Food and Drug Administration approved tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV PrEP in 2012. Since then, clinical trials and demonstration projects have supported the effectiveness of PrEP. But trials did not include adolescents younger than 18 so regulatory agencies were precluded from considering the approval of using TDF/FTC for minors.

Sybil G. Hosek, Ph.D., of the Cook County Health & Hospitals System's Stroger Hospital, Chicago, and coauthors designed Adolescent Medicine Trials Network for HIV/AIDS Interventions113 as an open-label demonstration project and phase 2 safety study for men who have sex with men who are ages 15 to 17 in the United States.

Study participants were recruited from clinics and community partners in six U.S. cities. They had negative HIV test results but were at high risk for and were willing to participate in a behavioral intervention and to accept TDF/FTC as PrEP, which they were provided daily for 48 weeks.

The study enrolled 78 participants with an average age of 16, of whom 29 percent were black, 14 percent were white and 21 percent were white Hispanic.

Over the 48 weeks, 23 sexually transmitted infections were diagnosed in 12 participants and three participants acquired an HIV infection during the study for an HIV seroconversion rate of 6.4 per 100 person-years, according to the results. Among those with seroconversion, tenofovir diphosphate levels were consistent with taking less than an average of two doses per week of the PrEP at the likely time of HIV infection.

Most of the participants had detectable PrEP drug levels throughout the study, with more than 95 percent of participants having detectable levels over the first 12 weeks of treatment with declining levels thereafter, the authors report, noting that challenges to medication adherence among adolescents are commonplace.

Study limitations include its small sample size.

"The waning adherence, especially with quarterly visits, demonstrates that more time, attention and resources may need to be allocated to adolescents who are seeking prevention services," the article concludes.

Explore further: Maraviroc-containing HIV PrEP regimens safe, well tolerated

More information: JAMA Pediatrics (2017). DOI: 10.1001/jamapediatrics.2017.2007

Related Stories

Maraviroc-containing HIV PrEP regimens safe, well tolerated

August 23, 2017
(HealthDay)—Maraviroc (MVC)-containing HIV pre-exposure prophylaxis (PrEP) regimens are well tolerated for preventing HIV infection in uninfected women, according to a study published online Aug. 22 in the Annals of Internal ...

In adolescents, oral Truvada and vaginal ring for HIV prevention are safe, acceptable

July 25, 2017
A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, two teams of investigators reported today at the 9th IAS Conference on HIV Science in Paris. ...

Effect of pre-exposure prophylaxis for HIV infection integrated with community health services

November 16, 2015
The rate of acquiring human immunodeficiency virus (HIV) was extremely low despite a high incidence of sexually transmitted infections (STIs) in a study where pre-exposure antiretroviral medication to prevent HIV infection ...

International study finds high levels of adherence to use of rectal microbicide gel

October 20, 2016
Participants enrolled in a rectal microbicide study were just as likely to follow through using an anti-HIV gel with anal sex as they were to using daily oral pre-exposure prophylaxis (PrEP), according to adherence results ...

Patient infected with HIV despite long-term adherence to PrEP

February 2, 2017
(HealthDay)—In a letter to the editor published in the Feb. 2 issue of the New England Journal of Medicine, authors present the case of a Canadian man infected with HIV despite long-term adherence to pre-exposure prophylaxis ...

Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

February 24, 2016
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk ...

Recommended for you

The effects of happiness and sadness on children's snack consumption

February 19, 2018
A University of Texas at Dallas psychologist has examined the preconceptions about the effects of emotions on children's eating habits, creating the framework for future studies of how dietary patterns evolve in early childhood.

Cycle of infant reflux signals a call to help mothers

February 14, 2018
Western Sydney University research has found that first-time mothers with mental health issues – in particular, maternal anxiety – are five times as likely to have their baby noted as having reflux when admitted to hospital.

Safe-sleep recommendations for infants have not reduced sudden deaths in newborns

February 14, 2018
An analysis of trends in sudden unexpected infant death (SUID) over the past two decades finds that the drop in such deaths that took place following release of the 1992 American Academy of Pediatrics (AAP) "back to sleep" ...

Most children with sickle cell anemia not receiving key medication to stay healthy

February 13, 2018
One of the greatest health threats to children with sickle cell anemia is getting a dangerous bacterial infection—but most are not receiving a key medication to reduce the risk, a new study suggests.

Premature babies' low blood pressure puzzle explained

February 13, 2018
Scientists have discovered crucial new information about how a foetus develops which could explain why very premature babies suffer low blood pressure and other health problems.

Babies face higher SIDS risk in certain states

February 12, 2018
(HealthDay)—Sudden infant death syndrome (SIDS) claims the lives of some 3,500 babies in the United States each year, but its toll is far heavier in some states than others, health officials report.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.